# Novobind Livestock Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novobind-livestock-therapeutics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.novobind.com
- Latest round: Series A (Jun 1, 2019)
- Investors on record: 7

## About

Based in Vancouver, Canada, and founded in 2012 by Filip Van Petegem, Hamlet Hovanessian Abnousi, Robert Fraser, Slade Loutet, and Sylvia Cheung, Novobind Livestock Therapeutics Inc., a.k.a. NovoBind operates as a biotechnology company that focuses on developing novel biotherapeutic solutions (NBXs) based on single-domain antibodies and complementary to conventional treatments. In April 2023, NovoBind received USD 0.030 million in grant funding from Invest Nova Scotia.

The company provides single domain antibodies (NBXs) that target pathogens that affect food production and food safety losses and have been materially affected by antibacterial resistance, regulatory ban, and changing human sentiments. These NBXs can be incorporated into feed, feed additives, water, or egg-based applications.

## Funding rounds

- Series A, Jun 1, 2019 — Seventure Partners, Lallemand Inc., Natural Products Canada, Mindset Venture Group, Lightheart Management Partners, The Center for Aquaculture Technologies, Carpere Ventures

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series A
- Lallemand Inc. — Series A
- Natural Products Canada (https://capitalatlas.ai/funds/natural-products-canada) — Series A
- Mindset Venture Group (https://capitalatlas.ai/funds/mindset-venture-group) — Series A
- Lightheart Management Partners (https://capitalatlas.ai/funds/lightheart-management-partners) — Series A
- The Center for Aquaculture Technologies — Series A
- Carpere Ventures — Series A